Brooks Labs Q1 FY27 Results: Revenue Falls 10% to Rs 22 Crore, PAT Halves to Rs 1 Crore
- August 14, 2026
- Posted by: Lakshit Sharma
- Category: Market
Brooks Labs Q1 FY27: Revenue Rs 22 Cr (-10% YoY). PAT Rs 1 Cr vs Rs 2 Cr (-46.48%). Gross profit Rs 1 Cr vs Rs 2 Cr. Consolidated. CMP Rs 65.60 on Aug 13.
Quick Answer
Brooks Labs reported a weak Q1 FY27 with consolidated revenue declining 10% to Rs 22 crore from Rs 25 crore in Q1 FY26. PAT nearly halved to Rs 1 crore from Rs 2 crore, with gross profit also contracting from Rs 2 crore to Rs 1 crore. Brooks Labs Q1 FY27 results reflect softer demand and margin compression in the laboratory chemicals and reagents segment, with both top-line and bottom-line declining proportionately.
Brooks Labs Q1 FY27 results showed the consolidated company posting a 10% revenue decline to Rs 22 crore from Rs 25 crore in Q1 FY26. The laboratory products company, which supplies chemicals, reagents, and diagnostic solutions to research and institutional customers, saw demand moderation in the April to June 2026 quarter.
The Brooks Labs Q1 FY27 results showed proportionate profit decline alongside the revenue contraction. Gross profit fell from Rs 2 crore to Rs 1 crore, and PAT declined from Rs 2 crore to Rs 1 crore, both broadly tracking the 10% revenue decline. The 46% PAT decline despite a 10% revenue fall points to the impact of fixed cost dilution on the lower revenue base.
Click Here – Get Free Investment Predictions
Brooks Labs Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Crore) | Q1 FY26 (Rs Crore) | YoY Change |
|---|---|---|---|
| Revenue | 22.00 | 25.00 | -10% |
| Gross Profit | 1.00 | 2.00 | -47.08% |
| Net Profit / PAT | 1.00 | 2.00 | -46.48% |
Brooks Labs Q1 FY27 Performance Analysis
Use the Univest Screener to track Brooks Labs live financials and Q1 FY27 results
Brooks Labs Q1 FY27 results reflect a challenging quarter for the laboratory products business. Revenue falling 10% to Rs 22 crore indicates softer institutional procurement from research laboratories, universities, and diagnostic centres that typically drive demand for laboratory chemicals and reagents.
The gross profit decline in Brooks Labs Q1 FY27 results from Rs 2 crore to Rs 1 crore, at 47%, is steeper than the 10% revenue decline. This disproportionate gross profit fall points to either fixed production or procurement costs that could not be reduced proportionately with volume, or a shift in product mix toward lower-margin laboratory supplies.
PAT at Rs 1 crore in Brooks Labs Q1 FY27 results represents a solid earnings base for a company this size, but the near-halving from Rs 2 crore in Q1 FY26 raises questions about operating leverage at lower revenue levels. If the 10% revenue shortfall persists into Q2 and Q3 FY27, cumulative PAT impact could be meaningful.
Revenue recovery will be the key driver for Brooks Labs to restore the profitability levels of Q1 FY26. The laboratory chemicals sector benefits from structural demand growth from India’s expanding research, pharmaceutical, and diagnostics sectors, suggesting the Q1 FY27 revenue dip may be temporary.
Key Business Factors in Q1 FY27
Institutional Procurement Cycles
Laboratory chemical and reagent purchases by research institutions, universities, and diagnostic laboratories often follow procurement cycles. Brooks Labs Q1 FY27 results may reflect a cycle where institutional purchase orders were lower than usual in Q1, which could normalise in Q2 FY27.
Gross Margin Compression
Gross profit declining 47% on 10% revenue decline in Brooks Labs Q1 FY27 results indicates that the company has a semi-fixed cost of goods structure. When volumes fall, the cost of maintaining laboratory-grade product quality and regulatory compliance does not decline proportionately.
Competition in Laboratory Supplies
The laboratory chemicals and reagents market includes domestic players and multinational companies. Any intensification of competition through pricing or expanded product offerings could weigh on Brooks Labs’s realisations and margins beyond Q1 FY27 results.
Dividend Details
Brooks Labs has not declared a dividend for Q1 FY27. The company may consider annual dividend distribution based on full-year performance, but Q1 FY27 results show reduced earnings that may temper dividend expectations.
FY27 Outlook
The FY27 outlook for Brooks Labs is cautiously constructive. India’s expanding pharmaceuticals, biotechnology, and diagnostics sectors drive structural demand for laboratory chemicals and reagents. If institutional procurement normalises in Q2 FY27, revenue should recover toward or beyond the Q1 FY26 base.
Key monitorables following Brooks Labs Q1 FY27 results include the order book for Q2 FY27, new customer additions, and any new product launches that could expand the company’s addressable market in the laboratory chemicals space.
Brooks Labs Stock Performance
Download the Univest iOS App or Univest Android App to track Brooks Labs share price live and stay updated on quarterly results.
Brooks Labs shares traded at Rs 65.60 on August 13, 2026, up 4.99% on the day despite the weak Q1 FY27 results, which may reflect short-term trading dynamics or optimism about a Q2 recovery. The stock’s valuation should be assessed against the company’s full-year earnings trajectory.
Key Risks
Revenue Recovery Uncertainty
If the 10% revenue decline in Brooks Labs Q1 FY27 results reflects structural demand softness rather than cyclical procurement timing, the recovery to FY26 revenue levels could take longer than anticipated.
Gross Margin Vulnerability
With gross profit declining 47% on 10% revenue fall, Brooks Labs has meaningful operating leverage risk. Any further revenue pressure in Q2 or Q3 FY27 could push PAT significantly below the Rs 1 crore Q1 FY27 results level.
Competitive Pricing Pressure
Laboratory supply markets see significant pricing pressure from larger international players and low-cost domestic competitors. Maintaining product pricing that supports positive gross margins is an ongoing challenge for mid-size laboratory product companies.
Conclusion
Brooks Labs Q1 FY27 results showed a weak quarter with revenue declining 10% to Rs 22 crore and PAT nearly halving to Rs 1 crore from Rs 2 crore in Q1 FY26. The proportionate gross profit decline points to operating leverage working against the company when revenues fall.
Revenue recovery in Q2 FY27 is the key catalyst for improving from the Brooks Labs Q1 FY27 results base. The structural demand outlook for laboratory chemicals in India is positive, supporting medium-term recovery. Consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Brooks Labs Q1 FY27 Results
When were Brooks Labs Q1 FY27 results announced?
Ans. Brooks Labs Q1 FY27 results were announced on August 13, 2026, covering the April to June 2026 quarter on a consolidated basis.
What was Brooks Labs’ revenue in Q1 FY27?
Ans. Brooks Labs reported consolidated revenue of Rs 22 crore in Q1 FY27, down 10% from Rs 25 crore in Q1 FY26.
What was Brooks Labs’ PAT in Q1 FY27?
Ans. Brooks Labs’ net profit (PAT) was Rs 1 crore in Q1 FY27, down 46.48% from Rs 2 crore in Q1 FY26.
Why did Brooks Labs’ PAT fall more than its revenue in Q1 FY27?
Ans. In Brooks Labs Q1 FY27 results, gross profit fell 47% on a 10% revenue decline due to semi-fixed costs in laboratory product procurement and quality maintenance. This operating leverage effect resulted in disproportionate PAT decline relative to the revenue fall.
Did Brooks Labs declare a dividend after Q1 FY27 results?
Ans. Brooks Labs has not declared a dividend for Q1 FY27.
What is the outlook for Brooks Labs after Q1 FY27 results?
Ans. The FY27 outlook is cautiously positive, supported by structural demand growth in India’s laboratory and diagnostics sectors. Revenue recovery in Q2 FY27 will determine whether Q1 was a temporary setback.
Is Brooks Labs a good investment after Q1 FY27 results?
Ans. Brooks Labs Q1 FY27 results show a weak quarter but the business operates in a structurally growing sector. Investors should monitor Q2 FY27 results for recovery before investing. Consult a SEBI-registered advisor.